[
  {
    "ts": null,
    "headline": "Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial",
    "summary": "Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented in a late-b",
    "url": "https://finnhub.io/api/news?id=af97c422b079601c87b6aa0b7d74808293fb6ae15b6719dc9af2bec27333e4ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731787620,
      "headline": "Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial",
      "id": 131399645,
      "image": "https://media.zenfs.com/en/prnewswire.com/962de8e75d3175bf5f633a8797d8ef0d",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented in a late-b",
      "url": "https://finnhub.io/api/news?id=af97c422b079601c87b6aa0b7d74808293fb6ae15b6719dc9af2bec27333e4ab"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX",
    "summary": "Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX? Left Atrial Appendage Closure Device. Key findings from...",
    "url": "https://finnhub.io/api/news?id=48ad5a34468e43670f59a21f6ca911c81a30177be4c18e002d7ce36d1930b50f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731769620,
      "headline": "Boston Scientific Corporation Announces Positive Three-Year Primary Endpoint Results from the OPTION Global Clinical Trial of the Watchman FLX",
      "id": 131401221,
      "image": "",
      "related": "BSX",
      "source": "Finnhub",
      "summary": "Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX? Left Atrial Appendage Closure Device. Key findings from...",
      "url": "https://finnhub.io/api/news?id=48ad5a34468e43670f59a21f6ca911c81a30177be4c18e002d7ce36d1930b50f"
    }
  }
]